Will Cronos (TSX:CRON) Stock Move Higher After a 25% Decline Last Week?

What next for Cronos stock investors after a 74% decline since March 2019?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Shares of leading cannabis company Cronos Group (TSX:CRON)(NASDAQ:CRON) fell over 25% in the last week. Why did Cronos Group investors lose a quarter of their market value in the week ended on November 15, 2019?

Cronos Group announced its third-quarter results on November 12 and reported sales of $12.7 million — 238% higher compared to sales of $3.76 million in the prior-year period. It’s adjusted earnings per share (EPS) rose from -$0.04 to $0.53 in the same period.

Though the company reported strong sales in Q3, it was around $3 million lower than consensus estimates and resulted in a sell-off. Further, cannabis giants such as Aurora Cannabis and Canopy Growth too reported underwhelming quarterly results last week, resulting in a bloodbath.

Key highlights for Cronos Group in Q3

In the third quarter, Cronos Group expanded its brand portfolio and included additional brands to target growth in the adult-use cannabis market. It closed the acquisition of Redwood in Q3. Redwood manufactures and distributes hemp-derived cannabidiol-infused skincare and personal care products.

These products are sold online and via premium retail and hospitality channels under the Lord Jones brand. In the September quarter, this brand launched several new products in the U.S. market. Lord Jones has partnered with luxury shoe brand owner Tamara Mellon to develop a hemp-derived CBD formula in the foot application space.

Lord Jones products are sold in 800 premium stores that include Sephora, SoulCycle, and Neiman Marcus. Cronos Group is looking to capitalize on the increasing demand of hemp-based CBD products with the Lord Jones brand.

The company is looking to gain leadership in the hemp-based CBD space and launched the Peace+ in the U.S. The Peace+ would begin selling hemp-derived CBD tincture products across 1,000 stores in the U.S.

What next for Cronos Group and investors?

In the third quarter, Cronos Group added Alberta to its domestic distribution network for adult-use products. The company believes the adult-use cannabis market in Canada is still in its infancy and has tremendous potential to grow over the next decade.

During the earnings call, Cronos Group CEO Michael Gorenstein stated, “The number of retail stores as well as warehousing and logistic needs are in the process of catching up to meet the demand of consumers. As a result, we are still not able to fully reach the long-term total addressable market represented by this population.”

Cronos Australia completed its IPO and raised $20 million in equity capital. Cronos Group holds a 31% ownership stake in Cronos Australia. The company wants to adopt an asset-light model in Australia and expects to import and distribute Peace Natural-branded products for the medical cannabis market in the country. This IPO will help Cronos accelerate growth in Australia and gain a strong foothold in medical cannabis in Asia-Pacific.

Cronos will work with farmers and suppliers to support capacity needs instead of vertically integrating the entire supply chain. The company hopes to improve operational efficiency with this model and drive profit margins higher.

Similar to peer cannabis companies, Cronos has focused on expanding its product portfolio via partnerships and acquisitions. It is optimistic about the ever-growing medical cannabis space globally and is spending millions in capital expenditure and research.

However, as we have seen that majority of sales are still dependent on Canadian sales. The slow rollout of retail stores and competition from illegal markets will weigh in on the top line, at least in the short term.

Cronos Group stock has already lost 74% in market value since March 2019. Has it bottomed out or will the bear run further decimate the stock as 2019 comes to a close?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.
Cannabis Stocks

Canopy Growth: Is There Budding Potential in the Cannabis Market?

Canopy Growth stock hit 52-week lows recently on news of needing to re-file on its BIoSteel business, so what now?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is…

Read more »

Cannabis smoke
Cannabis Stocks

Are Cannabis Stocks a Good Buy in May 2023?

If you're going to buy cannabis stocks, these are pretty much the only two I would consider. Even so, you…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Aurora Cannabis: Time to Light Up Your Portfolio?

Here's my take on whether Aurora Cannabis (TSX:ACB) is worth adding to a growth portfolio right now, given its growth…

Read more »

Target. Stand out from the crowd
Tech Stocks

These Undervalued TSX Stocks Are a Bargain in May 2023

If you're willing to bet on a rebound, these are the three TSX stocks I would consider first as they…

Read more »

A cannabis plant grows.
Cannabis Stocks

Tilray Stock Is Scraping 52-Week Lows: Will it Bottom Out Soon?

Tilray (TSX:TLRY) stock remains down 53% in the last year, but when will this company hit the bottom and start…

Read more »

Medicinal research is conducted on cannabis.
Metals and Mining Stocks

2 Canadian Stocks That Are Simply Too Cheap to Avoid

These two Canadian stocks have sunk lower and lower, which is why now could be the right time for long-term…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

1 Marijuana Stock I’d Buy Over Aurora Cannabis

Explore a promising marijuana stock that outshines Aurora Cannabis. Unveil the investment opportunity to boost your cannabis portfolio.

Read more »